Insider Selling: Natera Inc (NTRA) CFO Sells 108,108 Shares of Stock

Share on StockTwits

Natera Inc (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 108,108 shares of the business’s stock in a transaction dated Friday, September 14th. The stock was sold at an average price of $24.31, for a total transaction of $2,628,105.48. Following the sale, the chief financial officer now owns 22,000 shares in the company, valued at $534,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

  • On Monday, September 24th, Michael Burkes Brophy sold 446 shares of Natera stock. The stock was sold at an average price of $23.78, for a total transaction of $10,605.88.
  • On Monday, July 2nd, Michael Burkes Brophy sold 26,870 shares of Natera stock. The stock was sold at an average price of $18.29, for a total transaction of $491,452.30.
  • On Friday, June 22nd, Michael Burkes Brophy sold 266 shares of Natera stock. The stock was sold at an average price of $13.95, for a total transaction of $3,710.70.

Shares of NTRA stock traded up $0.66 during mid-day trading on Friday, reaching $20.77. The stock had a trading volume of 461,912 shares, compared to its average volume of 422,908. The stock has a market cap of $1.46 billion, a P/E ratio of -8.65 and a beta of 2.24. Natera Inc has a 12-month low of $8.60 and a 12-month high of $29.62. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of -3.32.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Wednesday, August 8th. The medical research company reported ($0.55) EPS for the quarter, hitting analysts’ consensus estimates of ($0.55). Natera had a negative return on equity of 752.93% and a negative net margin of 59.07%. The firm had revenue of $63.07 million during the quarter, compared to analysts’ expectations of $61.71 million. During the same quarter last year, the business posted ($0.55) EPS. The firm’s quarterly revenue was up 20.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Natera Inc will post -2.07 earnings per share for the current year.

A number of equities analysts recently issued reports on NTRA shares. JPMorgan Chase & Co. started coverage on Natera in a report on Friday, October 5th. They issued a “neutral” rating and a $26.00 price objective for the company. Morgan Stanley increased their price objective on Natera from $21.00 to $41.00 and gave the company an “overweight” rating in a report on Friday, September 28th. Canaccord Genuity increased their price target on Natera from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, August 16th. Zacks Investment Research raised Natera from a “sell” rating to a “hold” rating in a report on Thursday, June 21st. Finally, Robert W. Baird increased their price target on Natera from $17.00 to $20.00 and gave the stock an “outperform” rating in a report on Thursday, June 28th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $26.00.

A number of large investors have recently modified their holdings of the business. Bank of New York Mellon Corp boosted its stake in Natera by 9.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 650,968 shares of the medical research company’s stock worth $12,251,000 after buying an additional 58,224 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Natera in the 2nd quarter valued at about $313,000. Millennium Management LLC lifted its stake in shares of Natera by 135.5% in the 2nd quarter. Millennium Management LLC now owns 744,598 shares of the medical research company’s stock valued at $14,013,000 after purchasing an additional 428,376 shares in the last quarter. Macquarie Group Ltd. lifted its stake in shares of Natera by 9.0% in the 2nd quarter. Macquarie Group Ltd. now owns 1,714,886 shares of the medical research company’s stock valued at $32,274,000 after purchasing an additional 141,278 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Natera in the 2nd quarter valued at about $252,000. 66.31% of the stock is currently owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Story: Asset Allocation Models, Which is Right For You?

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.